Position in LLY
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$67,168
-$1,685,913 QoQ
Shares Held
56
-97.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#4,510
of 4,604 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Derivatives in LLY
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$29,985
PutShares
25
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Persistent Asset Partners Ltd holds $4,144,035 across 7 Drug Manufacturers - General names. LLY ranks #5 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
5,605 | $1,423,501 | |
| 2 | NVO |
Novo Nordisk A S
|
25,600 | $1,227,264 | |
| 3 | AZN |
Astrazeneca PLC
|
4,058 | $769,477 | |
| 4 | SNY |
Sanofi
|
14,750 | $629,235 | |
| 5 | LLY |
ELI LILLY & Co
This page
|
56 | $67,168 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
194 | $24,509 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
50 | $2,881 |
All Filings in LLY
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67,168 | 56 | Shares | Sole | 2026-08-07 | |
| 2026-06-30 | $29,985 | 25 | Put | Sole | 2026-08-07 | |
| 2026-03-31 | $1,753,081 | 1,906 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $572,804 | 533 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $1,570 | 23 | Call | Sole | 2025-08-11 | |
| 2025-06-30 | $2,653,520 | 3,404 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $3,706,684 | 4,488 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $1,133,296 | 1,468 | Shares | Other | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||